Sunrise, FL (Business Wire) 27 September 2010

Bioheart, Inc. (OTC Bulletin Board: BHRT) is one of the moderators of the medical device Emerging Medtech 40th Conference of the Partnership: Investment in Innovation (IN3) summit? 27 to 29 October in San Francisco, CA at the Grand Hyatt. IN3 events bring top / middle / end of the stage, the medical technology innovators with investors, venture capital, business development and senior – all in one forum.


IN3

Summit is the largest annual strategic partnerships and investments for the high-level executives in medical technology. Companies to venture capital and business customers are expected to hear the latest innovations and investment opportunities. Howard J. Leonhardt, Bioheart? S founder and Chief Science & Technology Officer presented the company’s products for the treatment of heart failure, including the flagship MyoCell, muscle stem cells in treating patients with advanced heart failure. The company in Heart Failure Society of America Meeting presented preliminary results of phase II / III MARVEL is a randomized, double-blind, placebo-controlled. MyoCell patients improved 91.7 meters in the six minute walk test, the primary endpoint of the study, while patients on placebo had decreased by 4 meters.

About Bioheart, Inc.

Bioheart committed to a leadership position in the cardiovascular industry technology-cells, providing cellular therapies, intelligent devices and biologics to meet the heart failure, lower limb ischemia, ischemic heart failure, acute myocardial infarction and other issues. Bioheart works to prevent the deterioration of the state with monitoring and diagnosis. The company’s articles of association? S aims to regenerate damaged tissue to allow, if possible, and to improve the quality of the lives of patients and health care costs and hospital stays.

specific biotechnology Bioheart on the discovery, development and focused, subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage, and peripheral vascular disease. MyoCell is a clinical cell therapy for muscular derivatives populate regions of scar tissue in a patient’s heart with new living cells for the purpose of improving cardiac function in patients with heart failure.

For more information on Bioheart visit www.bioheartinc.com.

Forward-Looking Statements:

Except for historical information are statements in this press release are forward looking and are based on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as “may,” “will,” “should,” “plan,” “expect,” “believe,” “anticipate,” “intend”, “may,” “would,” continue “estimate” or “” or the negative variations thereof or other similar expressions identify such forward-looking statements.

investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing, (ii) the ability to control and reduce our costs, (iii) our ability to build a distribution network and begin the distribution of certain products for our distribution rights (iv) complete our ability to quickly and successfully purchased our clinical studies, (v) the occurrence of unacceptable side effects during or after preclinical and clinical product candidates, (vi) to obtain the timing and the ability and maintain regulatory approvals for our product candidates (vii) dependence on the success of our lead compound, forecast to (viii) our inability to the extent of our future losses or if or when we are profitable, (ix) the ability to protect our intellectual property rights, and (x) an intensive competition. The Company is also subject to risks and uncertainties in its filings with the Securities and Exchange Commission, including under “Risk Factors” in the Annual Report on Form 10-K for the year ended 31 December 2009 described, and its Quarterly Report on Form 10-Q for the quarter ended 30 June 2010.


Contact

:

Catherine Sulawske Look, COO

954-835-1500

# # #

clear = “all”
Treatment of decompression